Kura Oncology, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
JPMorgan initiated coverage of Kura Oncology with an overweight rating and a $30 price target, citing strong sales of its approved cancer drug Komzifti and potential of its experimental drug darlifarnib. Komzifti's revenue grew from $2.1M to $9.1M in Q2 2026, with estimated peak sales of $1.5B. Shares were up 1% on Thursday.
JPMorgan initiated Kura Oncology (KURA) with an overweight rating and $30 price target, citing strong potential in its oncology drugs. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M. Insider purchases and positive analyst revisions also supported the stock, which has gained 28% over six months.
Kura Oncology's COO, Kathleen Ford, sold 10,574 shares for $111,930, at prices between $10.50 and $10.87. The sales were to cover taxes from vesting PSUs. Kura's stock is down 2.1% weekly but up 32.9% in six months. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M and adjusted loss of $0.77 per share. CEO Troy Wilson bought 100,000 shares. Analysts maintain a $24.00 price target.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning KURA (Kura Oncology, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.
Recent KURA coverage spans corporate actions, financial news and technology.
In the last 30 days, KURA insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($1.3M). The most active reporter was Powl Brian T., Chief Commercial Officer, with 3 filings. 60% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade and high price target suggest upside.
Analyst upgrade to overweight with a high price target suggests potential upside.
The insider sale may signal limited confidence and could weigh on the stock short term.
Positive preclinical data could lift Kura's stock on expectations of future partnership revenue.
Insider sale of modest size may signal limited confidence but unlikely to move price.
AlphAI scores every news story that mentions KURA with an AI model for sentiment and relevance, and aggregates insider trades from Kura Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
JPMorgan initiated coverage of Kura Oncology with an overweight rating and a $30 price target, citing strong sales of its approved cancer drug Komzifti and potential of its experimental drug darlifarnib. Komzifti's revenue grew from $2.1M to $9.1M in Q2 2026, with estimated peak sales of $1.5B. Shares were up 1% on Thursday.
2 min readJPMorgan initiated Kura Oncology (KURA) with an overweight rating and $30 price target, citing strong potential in its oncology drugs. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M. Insider purchases and positive analyst revisions also supported the stock, which has gained 28% over six months.
2 min readKura Oncology's COO, Kathleen Ford, sold 10,574 shares for $111,930, at prices between $10.50 and $10.87. The sales were to cover taxes from vesting PSUs. Kura's stock is down 2.1% weekly but up 32.9% in six months. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M and adjusted loss of $0.77 per share. CEO Troy Wilson bought 100,000 shares. Analysts maintain a $24.00 price target.
1 min readCaspian Therapeutics and Kura Oncology presented preclinical data on KO-7246, a menin inhibitor, showing potential for diabetes treatment. KO-7246 regenerated β-cell mass and controlled glycemic levels in Type 1 and Type 2 diabetes models. Caspian aims to develop KO-7246 as a best-in-class therapy, with an investor event scheduled for October 13, 2026.
3 min readBurrows Francis (Chief Scientific Officer) sold 20,726 shares of Kura Oncology, Inc. (KURA) at $10.83 ($0.22M total) on 2026-09-24.
1 min readKura Oncology (KURA) contributed KO-7246 to Caspian Therapeutics, receiving equity, reimbursement, and service fees. Caspian raised $50M for diabetes and cardiometabolic programs. Kura retains partial ownership and board representation. Kura's core focus remains ziftomenib in AML, with analysts projecting $353.2M revenue and $67.2M earnings by 2029. The Caspian deal adds cardiometabolic upside without significant R&D spending for Kura.
3 min readKura Oncology spun out Caspian, a diabetes-focused company, with $50m in funding led by BVF Partners. Kura retains 50% ownership. Caspian will develop KO-7246, a menin inhibitor for diabetes, using the funds for IND-enabling studies and a second undisclosed inhibitor. Investors include Eli Lilly and T1D Fund.
2 min readKura Oncology's research on a leukemia drug targeting menin showed potential for treating diabetes. The company launched Caspian Therapeutics with $50M in funding to develop menin inhibitors for diabetes and other cardiometabolic diseases. Kura retains 50% ownership, and Caspian will advance its lead drug through early-phase trials.
2 min readKura Oncology (KRRA) launched Caspian Therapeutics with $50M to develop menin inhibitors for diabetes and cardiovascular diseases. Caspian, 50% owned by Kura, aims to start Phase 1 trials for KO-7246 by 2025. Backers include the T1D Fund and Eli Lilly (LLY).
2 min readKura Oncology, Inc. (KURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointe
1 min read
